



Place de la France dans la recherche clinique vaccinale internationale

Etat des lieux (préliminaire), enjeux et opportunités

Eric Quéméneur
Inserm / APRS / France Vaccins

Point de vue industriel (généraliste, pas spécifique vaccins !)

leem Rapport annuel sur l'Attractivité de la France pour la recherche clinique (14^{ème} édition, Mars 2025)

FR participe à 598 des 1173 études multinationales EU sur la période 2023 - S1 2024


→ 3^{ème} rang européen,

(essentiellement grâce au 2^{ème} rang en onco, en recul dans les autres domaines)

→ sur ces 598 essais industriels, 130 en co-sponsorship académique (58% en onco, seulement 13% en infectieux)

Le fort potentiel de 147 établissements de santé pour les essais industriels est reconnu mais...

- ✓ 59 centres coordonnateurs, et seulement 6 centres par essai en moyenne
- ✓ 184 jours en moyenne (en 2023) pour 1^{ère} inclusion



	France 2022	France 2023	Espagne 2022	Espagne 2023
Autorisation	87j	104j	56j	99j
Etapes post-autorisation	73j	80j	93j	63j
Total pour 1 ^{ère} inclusion	160j	184j	149j	162j

Classement du Top 5 par phase et par aire thérapeutique

Ph. I	Ph. II	Ph. III	Ph. 4		Onco.	Auto-infl.	CNS	Metabo.	Cardio.
1	1	1	3		1	1	1	3	1
4	2	2	1		4	2	3	1	2 ex
2	3	4	2		2	4	5	5	5
3	4	5	4		5	4	5	2	2 ex
5	5	3	5		3	5	4	4	4



Messages clefs

- Perte de vitesse de l'Europe dans le Monde (19% des essais mondiaux, vs 28% Amérique et 60% Asie)
- Stagnation de la France en Europe, qui tient grâce aux essais précoces en oncologie

Recommandations

- Pour renforcer la place de l'Europe dans le monde
 - Essais précoces pour patients sans option thérapeutique
 - Mise en place fast track européen (autorisation en 31 j. au lieu des 100 j. actuels via CTIS)
- Pour renforcer la place de la France dans l'Europe
 - Convention unique + forfait par visite de patient
 - Accélérer la décentralisation des essais

TOP 5 des pays accueillants des recherches cliniques en Europe




- Pour les études à promotion industrielle, l'Espagne garde la 1^{ère} place
- L'Allemagne a perdu deux places en 2024 au profit de la France et de UK

Source clinicaltrial.gov (extraction le 16 janvier 2025)

International positioning of French vaccinologists

A basic analysis via Science LeadR; query 'vaccin*'



Based on

i) number of trial investigators; ii) number of authors

Country	Experts
United States	2433
France	630
United Kingdom	498
Germany	353
Spain	281
Canada	261
Australia	255
Netherlands	250
Italy	243
Brazil	218
Switzerland	209
Denmark	144
India	140

/ 7699

Country	Experts
United States	41236
Italy	10754
United Kingdom	9769
Japan	8111
Germany	7311
Spain	5800
India	5454
France	4953
Canada	4741
Australia	4400
Brazil	4281

/ 165319




an AI-powered platform that identifies top medical and scientific experts, facilitates collaborations, and tracks research impact through its proprietary Science Leader Reputation (SLR) score.

Ne pas surinterpréter mais on perçoit bien l'importance du potentiel de développement clinique pour notre compétitivité internationale


International positioning of French vaccinologists / mRNA vaccines

Global landscape of mRNA vaccine clinical trials: a systematic analysis of ClinicalTrials.gov data.

Liu S, Zhou T, Wang M, Xiang W and Wu J (2026) *Front. Public Health* 14:1738942.



325 trials
All domains; IDs + NCDs
(2000-2025)



	Number (%)	
	Total	Europe
Domestic	187 (69.5)	17 (22.1)
International	82 (30.5)	60 (77.9)

Funder type		
	Total	Europe
Industry	164 (61.0)	33 (42.9)
GOV	5 (1.9)	5 (6.5)
NIH	7 (2.6)	0 (0.0)
Network	2 (0.7)	1 (1.3)
Others	91 (33.9)	38 (49.4)

	Number (%)	
	Total	Europe
Devpt stage		
Phase I	79 (29.4)	14 (1.3)
Phase II/III	37 (13.8)	11 (14.3)
Phase II	38 (14.1)	8 (10.4)
Phase II/III	16 (5.9)	6 (7.8)
Phase III	30 (11.2)	12 (15.6)
Phase IV	16 (5.9)	5 (6.5)
Other	53 (19.7)	21 (27.3)

Domination large de USA et Chine mais top 5 EU bien placé (63 essais au total).
Forte proportion d'études internationales (78% vs 30%)
Moindre proportion d'essais industriels (43% vs 61%)

From a global preparedness point of view

GHS INDEX GLOBAL HEALTH SECURITY INDEX 2021 report



Assessment and benchmarking of health security and related capabilities across 195 countries.

The quantitative index is calculated across 6 categories of criteria (37 indicators, and 171 questions) using publicly available information.

Three vaccine-related indicators:



1.6. Vaccination rates for measles in humans and food-and-mouth disease in livestock

3.1. Emergency preparedness and response planning

4.5. Capacity to test and approve new MCM

Global country ranking and evolution 2019-2021

Rank	Country	Score	Change
1	United States of America	75.9	-0.3
2	Australia	71.1	-2.1
3	Finland	70.9	-1.1
4	Canada	69.8	+2.2
5	Thailand	68.2	-0.7
6	Slovenia	67.8	-0.8
7	United Kingdom	67.2	-1.1
8	Germany	65.5	-0.2
9	South Korea	65.4	-0.5
10	Sweden	64.9	-1.5
11	Netherlands	64.7	-3.0
12	Denmark	64.4	-2.9
13	New Zealand	62.5	+6.7
=14	France	61.9	-0.7
=14	Latvia	61.9	+2.1
16	Armenia	61.8	-1.4
17	Spain	60.9	+0.5
18	Japan	60.5	+1.7

La capacité de R&D vaccinale contribue favorablement au score de la FR

World rank per category

Rank EU
8/43




Les collab internationales vues par les équipes FR



QUESTIONNAIRE SUR LES PROJETS COLLABORATIFS (mars 2026)

Une cinquantaine de Centres sollicités (CIC/CRC, SMIT, CRB, CMG, Lab Immuno)

- 36 réponses
- 25 (71%) déclarent collaborations
- Total de 120 collab, majoritairement nationales, 36 EU+ROW



Collaborations	N (%)
Nationales	84 (70%)
Européennes	20 (17%)
Internationales	16 (13%)

Réseaux et projets structurants

Etudes cliniques multicentriques

Europe

- EURL-PH-RESVIR (EU Reference Laboratory for Public Health for RESpiratory VIRuses)
- EVH (European Vaccine Hub)
- EUCLID (EUropean CLInical Trials Platform & Development)
- PROACT-EU (A European Proactive Adaptive Clinical Trials Network within EU-Responses)
- LIVE (Leading International Vaccinology Education MSc program)
- VITAL-IMI2 (Vaccines and Infectious Diseases in the Ageing PopuLation)
- SOLVE (Sustainable COVID-19 vaccination for long-term vaccine immunity and effectiveness)

- ASUNIVA
- HB07 IP-CURE-B
- MPOX BOOSTER
- PIPELINE-RSV
- SHINGR'HIV

International

- Biobanque ANRS (Côte d'Ivoire, Mali, Guinée, Sénégal, Mozambique, Espagne, Brésil, Norvège)
- id-DRIVE (Resp viruses surveillance study, successor COVIDRIVE-IMI in EU+Canada)
- GII (Sanofi-sponsored Global Influenza Initiative)

- CM VICTORY
- PREVAC
- PRISM
- PROVENT
- RECOVERY
- V503-049
- VYF03

Les études interventionnelles multicentriques



Europe

Study acronym	NCT, EuCT	Treatment	Condition	Phase	Sponsor	Enrolm	Nb of sites	FR sites	Partner countries	Dates
ASUNIVA	NCT05569239	OVX836	Influenza	2b	Osivax	2 850	16	Lyon, Paris, Rennes	BEL, FIN, GER	2025-2026
HB07 IP-CURE-B	NCT05045261	Selgantolimod (TLR8 agonist)	Chronic Hepatitis B	2	ANRS	100	8	Lyon, Marseille, Nancy, Paris	GER, ITA, SPA	2022-2024
MPOX BOOSTER	2024-518007-22-00	MVA-BN	Healthy, 65+	3	FHM Sweden	490	10	Paris(7), Bordeaux, Nantes, St Etienne	SWE, BEL, IRE	2025-
PIPELINE-RSV	NCT07232706 (FR) NCT07041190 (INT)	Abrysvo (Pfizer) + Beyfortus (Sanofi)	RSV	3	CH Annecy Penta Foundation	1 000	17 ND	Annecy, Lille, Paris(7), Chambéry, Metz, Roche s/ Yon, Dijon, Créteil, Nimes, Caen, Tours, Angers, St Etienne, Villefranche	0 (for FR study) ITA, NL, BE, UK, CH	2026-2029
SHINGR'HIV	NCT05575830	RZV, Shingrix (GSK)	HIV, 50+	4	CH Geneve	225	10	Bordeaux(2), Pessac	CH	2022-2026

International

CM VICTORY	NCT05085366	mRNA-1647 CMV	Healthy, 16-40	3	Moderna	7 454	296	Paris, Limoges, Montpellier, Lyon, St Etienne, Tours, Nantes, Roche s/Yon,	USA, CAN, AUS, BEL, EST, FIN, GER, ISR, ITA, SP, UK	2021-2025
PREVAC	NCT02876328	Ad26.ZEBOV+MVA-BN-Filo, rVSVΔG-ZEBOV-GP	Ebola; children + adults	2	NIAID (+ANRS +EDCTP)	4 789	6		Guinea, Liberia, Mali, Sierra Leone (+ UK)	2017-2023
PRISM	NCT07285213	AZD5148	C. difficile	2	AstraZeneca	230	111	Lyon, Montpellier, Nantes, Nimes, Paris(2), Tours	USA, CAN, AUS, JAP, DK, GER, GRE, HUN, SP, SWE, UK, ITA, POL	2025-2028
PROVENT	NCT04625725	AZD7442 (2 Mabs)	Covid-19	3	AstraZeneca	5 197	89	Clermont-Ferrand, Dijon, Roche s/ Yon, Lille, Limoges, Nantes, Paris(2), St Etienne, Tours	USA, BEL, SPA, UK	2020-2023
RECOVERY	NCT04381936 2023-507441-29-00	Various options	Pneumonia (Covid, Flu, CAP)	3	Univ Oxford	70 000	>100	Strasbourg, Paris, Angers, Limoges, Lyon, Lille, Nice, Tours, Toulouse, Garches, Paris, Bordeaux	Asia (NEP, INDO), Africa (RSA, GHA), Eur (UK, BE, EST, NL, FR, IT, PORT, RO, SP, SW),	2020-2026
V503-049	NCT04199689	9vHPV (Gardasil)	Oral persistent Infection, Men 20-45	3	MSD	6 033	103	Dijon, Montpellier, Paris-Cochin, Rennes, Nantes	USA, BRA, COL, MEX, COL, PER, JAP, SKO, TW, THA BEL, CZ, GER, ISR, ITA, ESP	2020-2028
VYF03	NCT05011123	Stamaril versus Invest-vYF(Vero)	Yellow fever	2	Sanofi	690	23	Lyon(2), Montpellier, Nantes, Nimes, Paris	Eur (FIN, GER, ESP) Asia (SING, THAI)	2021-2027

Quelques données complémentaires



Clinical Trials


<https://euclinicaltrials.eu/>

This website allows you to search clinical trials initiated in the European Union and European Economic Area since 31 January 2022. For clinical trials initiated before 31 January 2022, see the [EU Clinical Trials Register](#).

➔ 125 'product=vaccine' sur 11 562 études dans la DB

➔ 23 'location=France'

4^{ème} ex aequo in EU



EU CT number	Protocol code	Title of the trial	Effectif	Pays	Sponsor
2024-513671-40-00	APHP200046	VAC-WARTS; nonavalent HPV vaccine in palmo-plantar warts	146	FR	AP-HP
2024-520140-42-00	2024/4031	BioHPV; Phase 3 nonavalent HPV vaccine in high grade squamous intraepithelial lesions	984	FR	Gustave Roussy
2025-521755-23-00	N/A	PIPELINE; Nirvesimab in infants ± maternal RSV vaccination	2000	FR	CH Annecy
2024-516098-62-00	P150957	CONDYVAC; quadrivalent HPV vaccine to prevent recurrence of external genital warts	300	FR	AP-HP
2025-521217-46-00	24CH249	MOCOVAC2; Impact of Flu vaccine on nasal and respiratory memory immune responses	30	FR	CHU St Etienne
2024-513081-19-00	HPV2-2303	HPV2-2303 - Phase 2, secondary HPV vaccination after tt of high-grade cervical lesions	85	FR	Oscar Lambret
2025-521307-43-00	N/A	Real-world study of chikungunya vaccination in populations at risk	1800	FR	CHU La Reunion
2024-510589-17-00	DR230330 – ANRS0514s	Phase I/II, booster dose of intranasal COVID-19 vaccine	238	FR	Inserm, CHRU Tours
2024-517411-73-00	24CH249	PREV-HOSPIT: 20-Valent pneumococcal conjugate vaccine (PCV-20) during acute febrile illness	1160	FR	CHU St Etienne
2024-518190-34-00	RC31/24/0156	Immune response in immunosuppressed pts with rheumatic diseases, including to rec ZV	60	FR	CHU Toulouse
2024-517288-22-01	HEMATOVAC	HEMATOVAC; Anti-pneumococcal Vacc (PCV13+PPV23 versus PREVENAR20) in Lymphoma	160	FR	CHU Poitiers
2024-513649-35-00	P170938J	SPLMENG0; phase III, assessing three meningococcal B vaccine strategies in pts with asplenia	84	FR	AP-HP
2023-504482-23-00	CHUBX 2022/40	Shingr'HIV; Recombinant Zoster Vaccine in HIV+ >50	80	FR	CHU Bordeaux
2024-517335-46-00	V940-011	INTerpath-011; Phase 2 Study of V940+BCG vs BCG in NMIBC	138	FR, IT, GE, POL, ESP, GRE, NL, HU.	MSD
2023-507187-39-00	17000139BLC3002	Phase 3, TAR-200±Cetrelimab vs intravesical BCG in PBCG-naïve HR_NMIBC	391	GE, ESP, CZ, NL, BE, PT, IT, POL, FR.	Janssen
2023-506236-32-00	V116-013	Phase 3, V116 in children with Increased Risk of Pneumococcal Disease.	215	SW, POL, FR, FIN, ESP.	MSD
2024-512865-15-00	DNTH103-MG-201	MAGIC; Phase 2, DNTH103 in adults with Myasthenia Gravis	54	DK, POL, FR, NL, NO, IT, CZ, SW, ESP.	Dianthus Inc.
2023-507746-83-00	MS700568_0183	MyClad; Phase 3, New form of oral Cladribine in Myasthenia Gravis	69	IT, POL, FR, GE, ESP, BE, BUL, CZ, HUN, ROM, SW.	Merck KGaA
2022-501974-21-00	V503-049	Phase 3, 9vHPV Vaccine for prevention of oral persistent HPV infection	1495	GE, CZ, IT, FR, BE, ESP.	MSD
2022-502047-35-00	VYF03	Investigational vYF Candidate vs Stamaril® in Adults	570	GE, FIN, ESP, FR.	Sanofi Pasteur
2023-504625-39-00	APL2-C3G-314	VALE; Pegcetacoplan in C3 Glomerulopathy	66	ESP, IT, CZ, FR, ESP, FR, NL, BE, AT, GE.	Apellis Inc.
2024-519743-15-00	INFQ-324-0476	Phase III High-Dose Influenza Vaccine in adults >60	1193	ESP, BUL, EST, FIN, FR, BE.	Abbott
2023-507906-15-00	COMB157G2399	Ofatumumab in relapsing multiple sclerosis	963	GE, LAT, NO, BE, NL, BE, NL, HUN, PT, POL, ESP, LIT, SVK, AT, SW, CZ, BUL, FIN, CRO, FR, DK, EST, GRE.	Novartis

13 études sponsors acad.;
FR seule

10 études sponsors indust.;
plusieurs pays EU

Les projets européens, un booster de collab pour les équipes FR

Projets vaccinaux associant des équipes françaises sur la période 2020-2025



EU program	Project Title	Project Acronym	Nb part	Coordinator	Equipes FR
2024					
HORIZON-JU-GH-EDCTP3-2024-01-02	A Multi-stage Malaria Vaccine for Control and Elimination	PfVIMT	8	IRD (France)	IRD
2023					
HORIZON-HLTH-2023-DISEASE-03-17	Sustainable COVID-19 vaccination for long-term vaccine immunity and effectiveness	SOLVE	10	ANRS-MIE, Inserm Transfert (France)	VRI ; Inserm/UPEC, CEA-IDMIT, Univ Bordeaux
HORIZON-HLTH-2023-DISEASE-03-17	Deconstructing the protective immunity of yellow fever virus 17D to inform flavivirus vaccine design	Yellow4FLAVI	13	Institut Pasteur (France)	Inserm Cochin
HORIZON-HLTH-2023-DISEASE-03-18	Development and characterization of a pan-flavivirus vaccine candidate	FLAVIVACCINE	10	IRD (France)	IRD, Institut Pasteur, CEA
HORIZON-HLTH-2023-DISEASE-03-18	Crimean-Congo Haemorrhagic Fever Vaccine and Immunotherapy	CCHFVACIM	15	FHOM (Sweden)	Inserm/P4, Institut Pasteur
HORIZON-HLTH-2023-DISEASE-03-18	Development of novel viral vectored vaccines against Marburgviruses inducing robust and cross-reactive protection	MARVAX	4	BNITM (Germany)	Institut Pasteur
HORIZON-HLTH-2023-DISEASE-03-18	Limiting West Nile Virus impact by novel vaccines and therapeutics approaches	LWNVIVAT	8	IrsiCaixa (Spain)	IRMB, U Montpellier-Inserm
HORIZON-JU-GH-EDCTP3-2023-02-01	Building multidisciplinary evidence to support Integrating Malaria VACcine with Seasonal malaria chemoprevention in West Africa	IMVACS	3	R-EvoWW (Italy)	Epicentre
2022					
HORIZON-HLTH-2022-DISEASE-06-02	Novel immunotherapies for tuberculosis and other mycobacterial diseases	ITHEMYC	11	TBVI (Netherlands)	Univ. Toulouse III, CNRS
HORIZON-HLTH-2022-DISEASE-06-02	Next Generation Vaccine Platform Leveraging Skin Immunity to Provide Disease-Modifying Treatment of Parkinson's Disease	NEXGEN-PD	11	Tridem Bioscience (Austria)	Motac neuroscience (CRO)
HORIZON-HLTH-2022-DISEASE-06-03	Optimising a high efficacy <i>Plasmodium vivax</i> malaria vaccine	OptiViVax	10	RUMC (Netherlands), U Oxford (UK)	CIMI (Inserm, CNRS, Sorbonne U)
HORIZON-HLTH-2022-DISEASE-06-03	Immunopeptidomics-based Development of Next-Generation Bacterial mRNA Vaccines	BAXERNA 2.0	11	VIB VZW (Belgium)	Institut Pasteur
HORIZON-HLTH-2022-DISEASE-06-03	Innovative nasal vaccines to prevent pathogen colonization and infection in the upper respiratory tract	NOSEVAC	14	EVI (Germany)	IP Lille (Inserm, U Lille)
HORIZON-HLTH-2022-DISEASE-06-03	Improving understanding of lung immunity in tuberculosis to establish a diverse, innovative TB vaccine pipeline targeting mucosal immunity	TBVAC-HORIZON	19	TBVI (Netherlands)	UPS Toulouse, IP Lille, IP Paris
HORIZON-MSCA-2022-DN-01-01	A training network for the design of synthetic carbohydrate-based vaccines in the fight against multi-drug resistant nosocomial pathogen <i>Acinetobacter baumannii</i>	ACINETWORK	17	U Milano (Italy)	IRCM (Inserm, U Montpellier)
HORIZON-WIDERA-2022-TALENTS-03-01	From insightful science to innovative health: Strengthening translational capacity and talent interoperability in vaccine and biologic research & innovation	VISION	8	Institut Pasteur Tunis (Tunisia)	Institut Pasteur Paris, Millipore SAS
2021					
HORIZON-HLTH-2021-CORONA-01-02	Cohorts united against COVID-19 variants of interest: SARS-coV2 variants Evaluation in pRegnancy and paeDiatrics cohorts	VERDI	29	U Padova (Italy)	IPLESP Inserm, Sorbonne U
HORIZON-HLTH-2021-CORONA-01-01	Equine Polyclonal antibodies Immunotherapy against COVID-19/SARS-CoV2-VOC	EPIC-CROWN-2	4	Fabentech (France)	IRD (Montpellier)
HORIZON-EIC-2021-PATHFINDEROPEN-01	Yeast cell factory for mRNA bioproduction	Yscript	9	U Orleans (France)	CNRS/U Orleans, TWB Inrae
HORIZON-WIDERA-2021-ACCESS-03-01	Enhancing Cancer Vaccine Science for New Therapy Pathways; Polish partnerships for cancer vaccine research	CANVAS	4	University Gdansk (Poland)	CEA
2020					
IBA-SC1-CORONAVIRUS-2020-4	European Corona Vaccine Trial Accelerator Platform	VACCELERATE	34	Klinikum, U Koeln (Germany)	Inserm, I-REIVAC, ANRS-MIE
IMI2-2020-22-01	Preparing for RSV Immunisation and Surveillance in Europe	PROMISE	22	Univ. Edinburg (UK), UMC Utrecht (NL)	Sanofi
IMI2-2020-20-02	Innovations to accelerate vaccine development and manufacture	Inno4Vac	41	EVI (Germany)	Sanofi, IABS-EU
IMI2-2020-23-02	Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance	PrIMAVeRa AMR	17	EVI (Germany)	Institut Pasteur, U Grenoble-Alpes
MSCA-IF-2020	Hydrogel/Polymersome-based Subunit Vaccines in the Fight Against COVID-19	HYPOVACC	2	LCPO U Bordeaux/CNRS	LCPO U Bordeaux/CNRS

Les projets européens, un booster de collab pour les équipes FR

Projets vaccinaux associant des équipes françaises sur la période 2020-2025



EU program	Project Title	Project Acronym	Nb part	Coordinator	Equipes FR
2024					
HORIZON-JU-GH-EDCTP3-2024-01-02	A Multi-stage Malaria Vaccine for Control and Elimination	PfVIMT	8	IRD (France)	IRD
2023					
HORIZON-HLTH-2023-DISEASE-03-17	Sustainable COVID-19 vaccination for long-term vaccine immunity and effectiveness	SOLVE	10	ANRS-MIE, Inserm Transfert (France)	VRI ; Inserm/UPEC, CEA-IDMIT, Univ Bordeaux
HORIZON-HLTH-2023-DISEASE-03-17	Deconstructing the protective immunity of yellow fever virus 17D to inform flavivirus vaccine design	Yellow4FLAVI	13	Institut Pasteur (France)	Inserm Cochin
HORIZON-HLTH-2023-DISEASE-03-18	Development and characterization of a pan-flavivirus vaccine candidate	FLAVIVACCINE	10	IRD (France)	IRD, Institut Pasteur, CEA
HORIZON-HLTH-2023-DISEASE-03-18	Crimean-Congo Haemorrhagic Fever Vaccine and Immunotherapy	CCHFVACIM	15	FHOM (Sweden)	Inserm/P4, Institut Pasteur
HORIZON-HLTH-2023-DISEASE-03-18	Development of novel viral vectored vaccines against Marburgviruses inducing robust	MARVAX	4	BNITM (Germany)	Institut Pasteur
HORIZON-HLTH-2023-DISEASE-03-18					Montpellier-Inserm
HORIZON-JU-GH-EDCTP3-2023-01-01					UCLouvain, CNRS, Sorbonne U)
2022					
HORIZON-HLTH-2022-DISEASE-03-17					UCLouvain, CNRS, Sorbonne U)
HORIZON-HLTH-2022-DISEASE-03-17					UCLouvain, CNRS, Sorbonne U)
HORIZON-HLTH-2022-DISEASE-03-17					UCLouvain, CNRS, Sorbonne U)
HORIZON-HLTH-2022-DISEASE-03-17					UCLouvain, CNRS, Sorbonne U)
HORIZON-HLTH-2022-DISEASE-03-17					UCLouvain, CNRS, Sorbonne U)
HORIZON-HLTH-2022-DISEASE-06-03	Improving understanding of lung immunity in tuberculosis to establish a diverse, innovative TB vaccine pipeline targeting mucosal immunity	TBVAC-HORIZON	19	TBVI (Netherland)	UPS Toulouse, IP Lille, IP Paris
HORIZON-MSCA-2022-DN-01-01	A training network against multi-drug resistant tuberculosis				IRCM (Inserm, U Montpellier)
HORIZON-WIDERA-2022-TALENTS-03-01	From insightful scientists to interoperable talent				Institut Pasteur Paris, Millipore SAS
2021					
HORIZON-HLTH-2021-CORONA-01-02	Cohorts united against COVID-19 in pregnancy and postpartum				IPLESP Inserm, Sorbonne U
HORIZON-HLTH-2021-CORONA-01-01	Equine Polyclonal COVID-19 vaccines				IRD (Montpellier)
HORIZON-EIC-2021-PATHFINDEROPEN-01	Yeast cell factory for COVID-19 vaccine production				CNRS/U Orleans, TWB Inrae
HORIZON-WIDERA-2021-ACCESS-03-01	Enhancing Cancer vaccine research				CEA
2020					
IBA-SC1-CORONAVIRUS-2020-4	European Corona Vaccine Trial Accelerator Platform	VACCELERATE	34	Klinikum, U Koeln (Germany)	Inserm, I-REIVAC, ANRS-MIE
IMI2-2020-22-01	Preparing for RSV Immunisation and Surveillance in Europe	PROMISE	22	Univ. Edinburg (UK), UMC Utrecht (NL)	Sanofi
IMI2-2020-20-02	Innovations to accelerate vaccine development and manufacture	Inno4Vac	41	EVI (Germany)	Sanofi, IABS-EU
IMI2-2020-23-02	Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance	PrIMAVeRa AMR	17	EVI (Germany)	Institut Pasteur, U Grenoble-Alpes
MSCA-IF-2020	Hydrogel/Polymersome-based Subunit Vaccines in the Fight Against COVID-19	HYPOVACC	2	LCPO U Bordeaux/CNRS	LCPO U Bordeaux/CNRS

- ✓ Vaccino soutenue par tous les instruments (HLTH, JU/EDCTP, EIC, IMI2)
- ✓ 25 projets impliquant FR, représentant ~24% des projets du domaine (total ~103)
- ✓ 13/25 (52%) incluent un développement clinique, et 5 plus amont devraient se traduire par devpt clinique à l'horizon 3 ans
- ✓ Quelques partenaires EU 'privilegiés' que l'on retrouve dans nombreux projets, reflétant l'impact positif des politiques de réseaux
- ✓ 7/25 (28%) sont coordonnés par FR...

... c'est important pour améliorer le "taux de retour" !


	Aide EU (€)	Part FR (€)	%
Tous	294 493 947,87	70 292 811,68	23,9
Coord. FR	127 621 285,44	49 651 638,94	38,9
Coord. non FR	164 867 087,37	20 641 172,74	12,5

Place de la FR en recherche vaccinale amont ?



131 projets 'vaccin*' dans la période 2000-2024 dont 18 FR (13,7%)
(44 sur 2020-2024 dont 4 FR)

Call year	Acronym	Title	PI	ERC scheme
2024	RESPOND	COMPUTATIONAL SCANNING FOR RESPONDING CLONOTYPES IN IMMUNE REPERTOIRES	WALCZAK Aleksandra CNRS	2025-2026 ERC-POC
2024	DIPP-IMMUNE	DISSECTING PROTECTIVE AND PATHOGENIC LONG-LASTING HUMORAL IMMUNITY	MAHEVAS Matthieu Paris 12	2025-2030 ERC-COG
2021	HUMANIGE	IDENTIFICATION OF LONG-TERM THERAPEUTIC STRATEGY IN IGE-MEDIATED ALLERGY BY LEVERAGING HUMANIZED MODELS AND PATIENT SAMPLES	REBER Laurent INSERM	2023-2028 ERC-COG
2020	ROSALIND	ECOGENOMICS OF MOSQUITO-MICROBE SYMBIOSIS FOR NOVEL CONTROL STRATEGIES OF INFECTIOUS DISEASES	REVEILLAUD Julie Inrae	2021-2027 ERC-STG
2018	PGEN	AUTOMATED EVALUATION AND CORRECTION OF GENERATION BIAS IN IMMUNE RECEPTOR REPERTOIRES	WALCZAK Aleksandra CNRS	2019-2020 ERC-POC
2018	FUNCMAb	HIGH-THROUGHPUT SINGLE-CELL PHENOTYPIC ANALYSIS OF FUNCTIONAL ANTIBODY REPERTOIRES	EYER / BAUDRY Klaus / Jean ETH/ESPCI	2019-2024 ERC-STG
2016	STIMUNITY	PRECLINICAL VALIDATION OF A NOVEL IMMUNOGENIC COMPOSITION TO STIMULATE INNATE IMMUNITY	MANEL Nicolas Curie	2017-2018 ERC-POC
2016	1TOSTOPVAX	RNA VIRUS ATTENUATION BY ALTERING MUTATIONAL ROBUSTNESS	VIGNUZZI Marco Pasteur	2016-1018 ERC-POC
2016	STRUGGLE	STATISTICAL PHYSICS OF IMMUNE-VIRAL CO-EVOLUTION	WALCZAK Aleksandra CNRS	1017-2023 ERC-COG
2014	EVOLPROOF	ARE HPV VACCINES 'EVOLUTION-PROOF'? MULTILEVEL EVOLUTIONARY ECOLOGY OF HUMAN ONCOVIRUSES	ALIZON Samuel U Montp	2015-2022 ERC-COG
2014	NEURIMMUNE	NEURAL REGULATION OF IMMUNITY	UGOLINI Sophie INSERM	2015-2021 ERC-COG
2013	HUMANTIVIRUSES	HUMAN ANTIBODY RESPONSES TO VIRUSES	MOUQUET Hugo Pasteur	2014-2018 ERC-STG
2012	IMMUNODEATH	IMMUNOGENIC CELL DEATH IN ANTICANCER THERAPY	KROEMER Guido INSERM	2013-2018 ERC-ADG
2011	EOIMMUNOPOP	HUMAN EVOLUTIONARY IMMUNOGENOMICS: POPULATION GENETIC VARIATION IN IMMUNE RESPONSES	QUINTANA-MURCI Lluís Pasteur	2012-2017 ERC-STG
2011	MOLSTRUCT TRANSFO	MOLECULAR AND STRUCTURAL BIOLOGY OF BACTERIAL TRANSFORMATION	FRONZES Rémi Pasteur	2012-2016 ERC-STG
2010	GENTB	HUMAN GENETICS OF TUBERCULOSIS	ABEL Laurent INSERM	2011-2016 ERC-ADG
2009	RNAVIRUS POPDIVVAX	RNA VIRUS POPULATION DIVERSITY, VIRULENCE, ATTENUATION AND VACCINE DEVELOPMENT	VIGNUZZI Marco Pasteur	2009-2015 ERC-STG
2008	HEPCENT	MOLECULAR ANALYSIS OF HEPATITIS C VIRUS NEUTRALIZATION AND ENTRY FOR THE DEVELOPMENT OF NOVEL ANTIVIRAL	COSSET Francois Loic INSERM	2009-201 ERC-ADG



Une bonne place qui renvoie toutefois à la question plus générale du lien avec l'aval (délais, mécanismes, acteurs)

Place dans les initiatives partenariales public/privé européennes



Sur 234 projets au total:

19 vaccins (4 IMI; 15 IMI2; 0 IHI), among which 14 involving FR partners

26 conducting clinical trial (4 only in vaccines)

EVOVAC1,2,3 and PERISCOPE

Les 19 projets "pure vaccines"

Ebovac+ program

Acronym	Title	Indust. lead (EPPIA)	Coord acad./SME	FR teams (acad., SMEs)	Period	Total (k€)	EU grant (k€)	part FR (k€)	
EBODAC	Communication strategy and tools for optimizing the impact of Ebola vaccination deployment	Janssen (NL)	LSHTM (UK)	–	2014-2020	25 741	20 329	0	
EBOMAN	Manufacturing and development for rapid access Ebola vaccine	Janssen (NL)	Vibalogics (DE)	–	2014-2017	40 188	1 023	0	
EBOVAC1	Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen	Janssen (NL)	LSHTM (UK)	Inserm, U Bordeaux	2014-2021	98 045	58 337	654	
EBOVAC2	Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen: phase II	Janssen (NL)	Inserm (FR)	Inserm, U Bordeaux, U Creteil	2014-2021	50 711	27 791	16 058	
EBOVAC3	Bringing a prophylactic Ebola vaccine to licensure	Janssen (NL)	LSHTM (UK)	Inserm, U Bordeaux, U Paris Cité	2018-2024	50 980	29 403	3 515	
PEVIA	Pan Ebola vaccine innovative approach	–	AP-HP (FR)	APHP, CHRU Lille, CNRS, CEA, Oligovax, Vaxeal, Inserm	2017-2023	17 731	6 190	4 337	
VSV-EBOPLUS	Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV	–	Sclavo (IT)	–	2016-2023	15 431	8 554	0	
VSV-EBOVAC	Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV	–	UGeneva (CH), Sclavo (IT)	–	2015-2019	4 786	3 887	0	
iCONSENSUS	Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production	Sanofi (FR)	KTH (SW)	Iprasense	2018-2022	9 400	4 700	71	
Inno4Vac	Innovations to accelerate vaccine development and manufacture	–	EVI (DE)	IABS	2021-2027	39 343	18 600	388	
PERISCOPE	PERTussIS COrelates of Protection Europe	Sanofi (FR)	Radboud (NL)	CEA, IPLille, Inserm	2016-2022	29 927	21 000	2 300	
DRIVE	Development of Robust and Innovative Vaccine Effectiveness	Sanofi (FR)	FISABIO (ES)	IABS, Inserm, UCBLyon, APHP	2017-2022	10 000	9 000	2 112	
PRIMAVERA	Predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance	–	EVI (DE)	Pasteur Paris, UGA	2021-2026	9 250	6 500	526	
VAC2VAC	Vaccine lot to vaccine lot comparison by consistency testing	Sanofi (FR)	EVI (DE)	IABS	2016-2022	16 373	7 850	493	
VITAL	Vaccines and infectious diseases in the ageing population	–	UMC Utrecht (NL)	CNRS, Inserm, UStEtienne	2019-2024	12 427	5 500	442	
ADVANCE	Accelerated development of vaccine benefit-risk collaboration in Europe	GSK (BE)	P95 (BE), UBasel (CH)	–	2013-2019	11 344	5 000	0	
BioVacSafe	Biomarkers for Enhanced Vaccine Immunosafety	GSK (IT)	U Surrey (UK)	CEA	2012-2019	30 931	17 409	400	
FLUCOP	Standardization and development of assays for assessment of influenza vaccines correlates of protection	Sanofi (FR)	USiena/Sclavo (IT)	Quinten	2015-2022	13 833	6 100	130	
ZAPI	Zoonotic anticipation and preparedness initiative	Boehringer (FR)	Erasmus MC (NL)	IABS, Pasteur Paris, U Aix-Mrs					
Totaux						~506,11M€	268,77M€	32,9 (12%)	707

Les études cliniques hors EU

NIH U.S. National Library of Medicine

ClinicalTrials.gov

Search results

"intervention=vaccine" → 11 174 studies

+ "location=France" → 370


+ "start=01-01-2020" → 143

Interventional: 101
Observational: 42

Phase 1: 39
Phase 2: 31
Phase 3: 24
Phase 4: 11
NA: 26


Industry: 39
Non indust: 104

Nombre d'études FR
sur la période Jan 2020 – Mar 2026
et sous-ensembles en collab. internationales



USA	1227
UK	148
France	143
Canada	136
Germany	130
Spain	127
Brazil	100
Belgium	93
South Korea	93
Italy	76
Japan	65
Netherlands	62
Switzerland	25

G7 hors US 698
Top5 EU (incl. UK) 641



Synthèse



Analyse préliminaire, résultats sont donc à prendre avec précaution !

- ✓ Un bon rang dans la compétition internationale ; FR souvent sur le podium, au coude à coude avec UK, GE et NL dans les catégories analysées
- ✓ Participation à nombreux réseaux et initiatives EU, plutôt en R&D amont.
- ✓ Quelques partenariats privilégiés en Europe. Voir sur la durée si ça se traduit par une meilleure capacité à capter des opportunités de développement.
- ✓ Présence des centres FR dans les études industrielles internationales. Un potentiel à confirmer et à cultiver. Dans un contexte de forte concurrence entre Europe et Amérique/Asie (-35% depuis 2000), intéressant de réfléchir à la valeur ajoutée du réseau I-REIVAC

Indicateurs non pris en compte à ce stade: publications, brevets, memberships, accords institutionnels...

Première étape, photo d'un état initial ! Analyse à poursuivre et affiner au service d'une stratégie à définir.



Bien que le développement international n'ait pas été une priorité collective, les membres du réseau apparaissent en bonne place dans ce bilan, engagés dans une dizaine de réseaux EU et plusieurs études pivotales internationales.

Possibilités de construire une proposition forte grâce au couplage France Vaccins-IREIVAC

Opportunités



EU Calls 2026-2027

- [HORIZON-HLTH-2026-01-DISEASE-04](#)
Development of novel vaccines for viral pathogens with epidemic potential
Ouverture: 10 février 2026; Clôture: 16 avril 2026. Budget : €44 200 000
Develop existing prophylactic and therapeutic vaccine candidates targeting exclusively one of the following viruses:
Junin mammarenavirus, Lassa mammarenavirus, Andes virus, Hantaan virus, Sin Nombre virus, Hendra virus, Enterovirus D68, Venezuelan equine encephalitis virus
- [HORIZON TMA MSCA-2026-DN-01-01](#)
Doctoral Networks – Joint Doctorates
Ouverture: 28 mai 2026; Clôture: 24 novembre 2026. Budget €593 033 846
DN "regular" et "ID", 48 mois max. (540 p.m., soit 15 doct./36 months); DN-JD, 60 mois max (540 pm, soit 11 doct. pour 48 mois)
- [European Vaccine Hub](#)
- [Be Ready Now](#)
- [CEPI](#)

Programmation EU/FP10, notamment besoins et ambitions hors du cadre 'pandemic preparedness' considéré comme déjà bien couvert par EC.

- [Evènement France Vaccins à B\(ruxelles\) \(16 octobre 2026\)](#)
- [Discussion en cours avec LEEM, G5 et EFPIA/Vaccines Europe \(pour IHI2 ?\)](#)

Nous organiser en mode 'coopétitif'



Remerciements

- Julie Jouan, Louise Lefrançois (I-REIVAC)
+ tous les membres du réseau qui ont répondu au questionnaire
- Aude Rimbault, David Vaudry (Inserm DPRE)
- Vania Rosas Magallanes, Sheyla Meija Gervacio, Virginie Sivan (DGRI/DAEI)
- Bertrand Schwartz (APRS)